The inhibition of the BRAFV600E gene mutation through BRAF and MEK-inhibitors is an established treatment in a variety of cancers including melanoma, thyroid cancer and non-small cell lung cancer (NSCLC). Here, MAP2K7 is linked to non-small cell lung carcinoma.